Table 1.
Comparison between HIV-infected and control groups.
| Characteristic | HIV-infected group (N = 50) No. (%) |
HIV-uninfected group (N = 50) No. (%) |
P value |
|---|---|---|---|
| Age (mean ± SEM) | 42 ± 1.2 | 42 ± 1.3 | 0.98 |
| Sex | 1.00 | ||
| Men | 33 (66%) | 33 (66%) | |
| Women | 17 (34%) | 17 (34%) | |
| Race | 1.00 | ||
| White | 24 (48%) | 24 (50%) | |
| African–American | 25 (50%) | 25 (50%) | |
| Other | 1 (2%) | 1 (2%) | |
| Mean BMI (kg/m2 ± SEM) | 28.7 ± 0.9 | 30.2 ± 0.9 | 0.23 |
| Current smoker | 15 (30%) | 9 (18%) | 0.16 |
| Diagnosis of hypertension | 15 (30%) | 14 (28%) | 0.83 |
| Family history of cardiovascular disease | 16 (32%) | 11 (22%) | 0.23 |
| Use of lipid-lowering therapy | 12 (24%) | 3 (6%) | 0.03* |
| Diagnosis of metabolic syndrome | 15 (30%) | 9 (18%) | 0.24 |
| Mean fasting LDL (mg/dl ± SEM) | 98 ± 4 | 114 ± 4 | <0.01* |
| Mean fasting HDL (mg/dl ± SEM) | 47 ± 2 | 56 ± 2 | <0.01* |
| Mean fasting triglycerides (mg/dl ± SEM) | 141 ± 11 | 103 ± 7 | <0.01* |
| Mean fasting glucose (mg/dl ± SEM) | 89 ± 1 | 84 ± 2 | <0.01* |
| Mean fasting insulin (µU/ml) | 13.9 ± 1.9 | 13.0 ± 1.7 | 0.72 |
| Mean HOMA-IR | 3.1 ± 0.5 | 2.7 ± 0.3 | 0.50 |
| Mean hsCRP (mg/l) | 4.1 ± 0.6 | 6.0 ± 1.0 | 0.10 |
| Mean 10-year Framingham risk score | 0.3 ± 0.8 | −0.8 ± 0.8 | 0.38 |
| Resting brachial artery diameter (mm) | 3.9 ± 0.1 | 3.8 ± 0.1 | 0.56 |
| Mean brachial FMD (% ± SEM) | 12.0 ± 0.9 | 13.3 ± 1.0 | 0.30 |
| Mean CIMT (mm ± SEM) | 0.68 ± 0.02 | 0.68 ± 0.02 | 0.96 |
BMI, body mass index; CIMT, carotid intima–media thickness; FMD, flow-mediated vasodilation; HDL, high-density lipoprotein; HOMA-IR, homeostatic model of insulin resistance; hsCRP, highly-sensitive C-reactive protein; LDL, low-density lipoprotein.
*
P ≤ 0.05.